Lactoserum (Dermacyd Femina®) and Prevention of Recurrence of Bacterial Vaginosis
NCT ID: NCT00556179
Last Updated: 2009-01-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
122 participants
INTERVENTIONAL
2007-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Dermacyd Femina Pocket BR (Lactic Acid)- Acceptability.
NCT00794612
Acceptability Dermacyd Wipes - Lactoserum - Hygiene
NCT00397527
Safety Dermatological Evaluation: Acceptability With Gynecological Follow up - Dermacyd Delicata Pocket BR
NCT00663390
Acceptability Lactoserum (Dermacyd Delicata - New Fragrance)
NCT00497783
Acceptability Dermacyd Delicata - New Fragrance - Lactoserum - Hygiene
NCT00370162
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Lactoserum (Dermacyd Femina®)
Once a day during three months
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Lactoserum (Dermacyd Femina®)
Once a day during three months
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Confirmed cure of bacterial vaginosis after treatment with oral metronidazole.
* Vaginal bacterioscopic examination negative for candida and trichomonas.
Exclusion Criteria
* Allergy to dermacyd
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
18 Years
50 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sanofi
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
sanofi-aventis
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jaderson Lima
Role: STUDY_DIRECTOR
Sanofi-aventis administrative office Brazil
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Sanofi-aventis
São Paulo, São Paulo, Brazil
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
LACTO_L_02399
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.